Sanofi is long standing partner to public health inKenya, Ghana & Ethiopiaand we have always put patient health at the center of what we do.
Our company is currently implementing its global strategic roadmap, aimed at transforming the practice of medicine by bringing new innovative medicines and vaccines while growing our business through core assets and by allocating more of our resources to fund our R&D pipeline
In several African countries, including in Kenya, Ghana & Ethiopia , Sanofi has launched a project to assess a new way of distributing medicines and vaccines in conjunction with a partner who has the capability to provide a first-class service for patients and healthcare professionals .
Our priority is to make sure that Sanofi’s medicines and vaccines continue to reach patientsin Kenya, Ghana & Ethiopia,in a sustainable way.
In August 2021, Sanofi signed an exclusive Master Agreement withE.P.DIS,the leading distributors of pharmaceutical products and services in Africa and the French oversea territories which will become its partner in the distribution and marketing of its medicines and vaccines in 25* African countries.
We are fully confident inE.P.DIS’sability to develop the Sanofi portfolio and capacity to perform all business’ activities into a full services approach by ensuring smooth business continuity.
Therefore, this project does not foresee any change for the physicians or patients in any way in accessing our drugs and vaccines, which will continue to be provided to patients in Kenya, Ghana & Ethiopia, irrespective of the future set-up.
We remain committed to the health of the population in Kenya, Ghana & Ethiopia and in all of the African countries covered by this partnership
Sanofi andE.P.DISare currently in the preparation phase to make the new organization go live by 1 October 2021 and will be able to share more details in the coming weeks & months.
*Ivory Coast; Cameroon; Senegal; Burkina Faso ; Congo ; Gabon ; Madagascar ; Mali ; Mauritania ;Ile Maurice Guinee equatorial ;Benin ; Tchad ; Democratic Republic of Congo; Guinee ; Niger ; Togo ; Botswana ; Namibia ; Uganda ; Zimbabwe ;Swaziland ; Ghana ; Kenya ; Ethiopia.
Contact for commercial and/or scientific information about our range of drugs
Stephane.gokou@sanofi.com
Contact for commercial and/or scientific information about our range of vaccines
idrissa.tiene@sanofi.com
Media Relations
aziz.yousfimalki@sanofi.com
Pharmacovigilance and medical information
Starting from January 1 st 2022, healthcare professionals, regardless of their location, will contact Eurapharma through its subsidiary Ethica:
For all African countries
pharmacovigilance.sanofi@groupe-ethica.com
Declarations related to the quality of drugs and vaccines
Starting from January 1, 2022, healthcare professionals should contact Eurapharma through its subsidiary Ethica :
French and English-speaking African countries
quality-complaint.sanofi@groupe-ethica.com